2 214

Cited 57 times in

Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer

Authors
 TaeJeong Oh  ;  Nayoung Kim  ;  Youngho Moon  ;  Myung Soon Kim  ;  Benjamin D. Hoehn  ;  Chan Hee Park  ;  Tae Soo Kim  ;  Nam Kyu Kim  ;  Hyun Cheol Chung  ;  Sungwhan An 
Citation
 JOURNAL OF MOLECULAR DIAGNOSTICS, Vol.15(4) : 498-507, 2013 
Journal Title
 JOURNAL OF MOLECULAR DIAGNOSTICS 
ISSN
 1525-1578 
Issue Date
2013
MeSH
Adult ; Aged, 80 and over ; Biomarkers, Tumor/blood* ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/diagnosis* ; Colorectal Neoplasms/genetics ; DNA Methylation ; Early Detection of Cancer ; Female ; Gene Expression Regulation, Neoplastic ; Genome, Human ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Syndecan-2/biosynthesis ; Syndecan-2/blood*
Keywords
Adult ; Aged, 80 and over ; Biomarkers, Tumor/blood* ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/diagnosis* ; Colorectal Neoplasms/genetics ; DNA Methylation ; Early Detection of Cancer ; Female ; Gene Expression Regulation, Neoplastic ; Genome, Human ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Syndecan-2/biosynthesis ; Syndecan-2/blood*
Abstract
Aberrant DNA methylation has shown promise as a biomarker for the early detection of cancer. To discover novel genes frequently methylated at an early stage in colorectal cancer (CRC), DNA microarray analysis coupled with enriched methylated DNA was performed in primary tumors and compared with adjacent nontumor tissues of 12 patients with CRC at stages I to IV. Stepwise filtering for candidate selection in microarray data analysis yielded a set of genes that are highly methylated across all CRC tumors and that can be used as a composite biomarker for CRC detection. Verification assay identified the SDC2 gene as a potential methylation biomarker for early CRC detection. In clinical validation in tissues from 139 CRC patients, a much higher level of aberrant SDC2 methylation was measured in most primary tumors (97.8%), compared with corresponding nontumor tissue of CRC patients, irrespective of clinical stage. Clinical validation of SDC2 methylation in serum DNA from CRC patients (n = 131) at stages I to IV and from healthy individuals (n = 125) by quantitative methylation-specific PCR demonstrated a high sensitivity of 87.0% (95% CI, 80.0% to 92.3%) in detecting cancers, with a specificity of 95.2% (95% CI, 89.8% to 98.2%). Importantly, sensitivity at stage I was 92.3%, indicating the potential of SDC2 methylation as a blood-based DNA test for early detection of CRC.
Full Text
http://www.sciencedirect.com/science/article/pii/S1525157813000585
DOI
10.1016/j.jmoldx.2013.03.004
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Nam Kyu(김남규) ORCID logo https://orcid.org/0000-0003-0639-5632
Park, Chan Hee(박찬희)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/87796
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse